Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyranosyl lipid A - Immune Design

Drug Profile

Glycopyranosyl lipid A - Immune Design

Alternative Names: G 100; GLA; GLA-SE; Glucopyranosyl lipid adjuvant; ID-G100

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune Design
  • Developer Immune Design; Merck & Co
  • Class Adjuvants; Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Follicular lymphoma
  • No development reported Merkel cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Late-stage disease, Metastatic disease) in USA (Intratumoural)
  • 16 Apr 2019 Roche, Immune Design, Institut Bergonié and National Cancer Institute, France plan the phase II AGADIR trial for Solid tumours (Late-stage disease, Combination therapy, Radiotherapy) in France in June 2019 (Intratumoural) (NCT03915678)
  • 02 Dec 2018 Efficacy data and immunogenicity data from a phase I/II trial in Follicular lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top